HDAC9 and rheumatoid arthritis: Our results showed that MPT0G009 was >10 times potent than the marketed HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) on HDACs inhibition in the human RA fibroblast-like synoviocytes and rabbit synovial fibroblast cell line, HIG-82.